Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics of the systemic lupus erythematosus study cohort

From: Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort

Demographic characteristics
 Number of patients 3215
 Women/Men 2925 (91%)/290 (9%)
 Age at SLE diagnosis, mean ± SD 37 ± 13 (range, 19–86 years)
 Age at the time of RELESSER-TRANS inclusion, mean ± SD 48 ± 14 (range, 19–94 years)
 Ethnic groups Caucasians: 93%/Hispanics: 5.4%/African-Americans: 0.2%/Asians: 0.6%/Others: 0.8%
 Tobacco Never: 58%/Before: 25%/At the time of RELESSER-TRANS inclusion: 17%
Clinical manifestations
 Constitutional symptoms Fever 3.6%/Weight loss 9.5%
 Cutaneous 64%
 Arthritis 78%
 Raynaud’s phenomenon 35%
 Vasculitis 10%
 Nephritis 31%
 Gastrointestinal involvement 3%
 Hepatitis 2.8%
 Pericarditis 15%
 Non-ischemic cardiac disease 4.5%
 Neuropsychiatric manifestations 6.5%
 Hematologic 79%
 Lymphadenopathy/Splenomegaly 9.7%/2.9%
 Secondary antiphospholipid syndrome 17%
 SLEDAI score, mean ± SD 2.62 ± 3.69
 SDI score, mean ± SD 1.15 ± 1.68
Immunological laboratory*
 Anti-dsDNA antibody positivity (available data in all patients) 72%
 Hypocomplementemia (available data in all patients) 76.5%
 Anti-Sm antibody positivity (available in 3048 patients) 21%
 Anti-Ro antibody positivity (available in 3109 patients) 40%
 Anti-La antibody positivity (available in 3108 patients) 19%
 Anti-RNP antibody positivity (available in 3095 patients) 25%
 Anticardiolipin antibody positivity [IgM or IgG] (available in 2952 patients) 20%
 Anti-beta 2 glycoprotein 1 [IgM or IgG] (available in 1918 patients) 13.5%
 Lupus anticoagulant (available in 2312 patients) 23%
Treatments**
Corticosteroids 88%
 <10 mg/daily of prednisone or equivalent 46.5%
 10–30 mg/daily 32%
 >30–60 mg/daily 21.5%
Antimalarials 83.5%
Methotrexate 17%
Azathioprine 31%
Cyclophosphamide 20%
Mycophenolate 16%
Intravenous immunoglobulins 4%
Plasmapheresis 1.5%
Rituximab 6%
Antiplatelet therapy 36%
Anticoagulants 14%
  1. Abbreviations: RELESSER-TRANS Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase, SD standard deviation, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
  2. *Because this is a retrospective (historical) study, not all analyzed variables were recorded in all included cases. Thus, the percentage for each variable was calculated for only those patients in which the data were documented
  3. ** Treatments recorded in the RELESSER-TRANS registry as “any use” or “use at last visit” (corresponding to the last visit before enrollment) or both